An open, multi-centre, phase IIIb, long term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency

Trial Profile

An open, multi-centre, phase IIIb, long term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Hydrocortisone (Primary)
  • Indications Adrenal insufficiency
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors DuoCort; Shire; ViroPharma Incorporated
  • Most Recent Events

    • 19 May 2017 New trial record
    • 14 Mar 2017 Results published in the European Journal of Endocrinology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top